Clinical details, graft composition, and outcomes in leukocyte antigen haplotype–mismatched transplant recipients receiving and not receiving granulocyte colony-stimulating factor (G-CSF) after transplantation
| Characteristic . | G-CSF* (n = 43; 1995-1998)3 . | No G-CSF (n = 36; 1999-2000) . |
|---|---|---|
| Mean (range) age, y | 22 (4-53) | 30 (11-60) |
| Disease | ||
| Acute myeloblastic leukemia | 20 | 20 |
| Acute lymphoblastic leukemia | 23 | 16 |
| Status at transplantation | ||
| Poor-risk complete remission | 7 | 7 |
| Beyond second complete remission | 21 | 15 |
| Chemoresistant relapse | 15 | 14 |
| Graft processing | E-ros + Ceprate | MACS |
| Graft composition | ||
| Mean (range) CD34+ × 106/kg | 10.8 (3.1-27.5) | 12.1 (5.1-25.4) |
| Mean (range) CD3+ × 104/kg† | 2.0 (0.1-4.2) | 1.1 (0.1-3) |
| Mean (range) percentage of CD14+cells | 11.8 (0.8-51.8) | < 2 |
| No. (%) of primary engraftments | 41 (95.3) | 34 (93) |
| Neutrophils > 0.5 × 109/L (day after transplantation) | 9 | 13 |
| Platelets > 50 × 109/L (day after transplantation) | 18 | 17 |
| No. (%) of deaths during remission | 15/43 (35) | 9/36 (25)‡ |
| No. (%) of relapses | 15/43 (35) | 9/36 (25)‡ |
| No. (%) of cases of acute GVHD | 0 | 4 |
| Characteristic . | G-CSF* (n = 43; 1995-1998)3 . | No G-CSF (n = 36; 1999-2000) . |
|---|---|---|
| Mean (range) age, y | 22 (4-53) | 30 (11-60) |
| Disease | ||
| Acute myeloblastic leukemia | 20 | 20 |
| Acute lymphoblastic leukemia | 23 | 16 |
| Status at transplantation | ||
| Poor-risk complete remission | 7 | 7 |
| Beyond second complete remission | 21 | 15 |
| Chemoresistant relapse | 15 | 14 |
| Graft processing | E-ros + Ceprate | MACS |
| Graft composition | ||
| Mean (range) CD34+ × 106/kg | 10.8 (3.1-27.5) | 12.1 (5.1-25.4) |
| Mean (range) CD3+ × 104/kg† | 2.0 (0.1-4.2) | 1.1 (0.1-3) |
| Mean (range) percentage of CD14+cells | 11.8 (0.8-51.8) | < 2 |
| No. (%) of primary engraftments | 41 (95.3) | 34 (93) |
| Neutrophils > 0.5 × 109/L (day after transplantation) | 9 | 13 |
| Platelets > 50 × 109/L (day after transplantation) | 18 | 17 |
| No. (%) of deaths during remission | 15/43 (35) | 9/36 (25)‡ |
| No. (%) of relapses | 15/43 (35) | 9/36 (25)‡ |
| No. (%) of cases of acute GVHD | 0 | 4 |
E-ros + Ceprate indicates sheep red blood cell rosetting plus positive selection of CD34+ cells with use of Ceprate SC columns; MACS, magnetically activated cell sorter; and GVHD, graft-versus-host disease.
G-CSF was given in a dosage of 5 μg/kg of body weight daily for the first 20 days after transplantation.
CD3+ T cells contained the same proportion (50%-70%) of CD4+ cells in the two series.
There were no significant differences between patients receiving G-CSF and those not receiving G-CSF (P = .34) as determined 270 days after transplantation.